Literature DB >> 31787615

Fine tuning of p53 functions between normal and leukemic cells: a new strategy for the treatment of chronic lymphocytic leukemia.

Tatjana Stankovic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31787615      PMCID： PMC6959186          DOI： 10.3324/haematol.2019.230896

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  26 in total

1.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

Authors:  Llorenç Coll-Mulet; Daniel Iglesias-Serret; Antonio F Santidrián; Ana M Cosialls; Mercè de Frias; Esther Castaño; Clara Campàs; Montserrat Barragán; Alberto Fernández de Sevilla; Alicia Domingo; Lyubomir T Vassilev; Gabriel Pons; Joan Gil
Journal:  Blood       Date:  2006-01-26       Impact factor: 22.113

2.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.

Authors:  Qingjie Ding; Zhuming Zhang; Jin-Jun Liu; Nan Jiang; Jing Zhang; Tina M Ross; Xin-Jie Chu; David Bartkovitz; Frank Podlaski; Cheryl Janson; Christian Tovar; Zoran M Filipovic; Brian Higgins; Kelli Glenn; Kathryn Packman; Lyubomir T Vassilev; Bradford Graves
Journal:  J Med Chem       Date:  2013-07-16       Impact factor: 7.446

Review 3.  Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.

Authors:  Rajendra N Damle; Carlo Calissano; Nicholas Chiorazzi
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

4.  The evolutionary biography of chronic lymphocytic leukemia.

Authors:  Xose S Puente; Carlos López-Otín
Journal:  Nat Genet       Date:  2013-02-24       Impact factor: 38.330

Review 5.  Management of chronic lymphocytic leukemia.

Authors:  Paolo Ghia; Michael Hallek
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

Review 6.  The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.

Authors:  Swethajit Biswas; Emma Killick; Aart G Jochemsen; John Lunec
Journal:  Expert Opin Investig Drugs       Date:  2014-02-28       Impact factor: 6.206

Review 7.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

8.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Authors:  Susan O'Brien; Richard R Furman; Steven Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff Sharman; William Wierda; Jeffrey Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Ying Luan; Danelle F James; Alvina D Chu; John C Byrd
Journal:  Blood       Date:  2018-02-02       Impact factor: 25.476

9.  p53 modifications: exquisite decorations of the powerful guardian.

Authors:  Yanqing Liu; Omid Tavana; Wei Gu
Journal:  J Mol Cell Biol       Date:  2019-07-19       Impact factor: 6.216

Review 10.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Authors:  Veronica Tisato; Rebecca Voltan; Arianna Gonelli; Paola Secchiero; Giorgio Zauli
Journal:  J Hematol Oncol       Date:  2017-07-03       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.